Keck Medicine of USC researchers trace origins of colorectal cancer tumor cells

Key points
- For the first time, Keck Medicine of the University of Southern California (USC) cancer researchers have traced the origins of colorectal cancer cells, finding important clues to why tumor cells become "good" or "bad," with the potential of stopping them before they start.
- The colon and rectum belong to our body's digestive system - together they are also known as the large bowel.
- A feeling that the bowel does not empty properly after a bowel movement.
- The scientists employed a "Big Bang" model of human colorectal cancer growth similar to the theory that the universe started from a single point and exploded outward.
For the first time, Keck Medicine of the University of Southern California (USC) cancer researchers have traced the origins of colorectal cancer cells, finding important clues to why tumor cells become "good" or "bad," with the potential of stopping them before they start.
The scientists employed a "Big Bang" model of human colorectal cancer growth similar to the theory that the universe started from a single point and exploded outward. The team was led by Keck faculty researchers Darryl Shibata, M.D., professor of pathology, Keck School of Medicine of USC and Christina Curtis, Ph.D., M.Sc., assistant professor of medicine and genetics at Stanford University and adjunct assistant professor, department of Preventive Medicine, Keck School of Medicine of USC.
"It's like going back in time," said Shibata. "The history of each tumor is written in its genomes. To prevent tumors, you want to see what happened early on and how to stop their first cell divisions."
By taking samples from opposite sides of colorectal tumors, the researchers reconstructed the first few divisions, which took place when the nascent tumors were too small to even detect. The tumor starts were abnormal, with a burst of new mutations. Moreover, even from the start, many cancer cells expressed the abnormal mobility or intermixing of cells that would allow them to eventually invade and metastasize in the body. By contrast, tumor cells destined to form benign adenomas did not intermix, indicating that some tumors are "born to be bad."
Understanding which tumors will kill and which ones are harmless is critical to patients making decisions about tumor removal and surgery, Shibata said.
The next step is to further explore what happens at the genesis of tumor cells, which Shibata and Curtis are currently studying. Curtis will also look into whether other cancers behave the same way as the colorectal cancers.
What is colorectal cancer? Any cancer - a growth, lump, tumor - of the colon and the rectum is a type of colorectal cancer. Colorectal cancer is also known as bowel cancer. The UK National Health Service says colorectal cancer is the most common cancer globally today. However, the World Health Organization says it is the second most common cancer, after lung cancer. A US study found that incidence rates among adults younger than age 50 years are increasing.
A colorectal cancer may be benign or malignant. Benign means the tumor will not spread, while a malignant tumor consists of cells that can spread to other parts of the body and damage them.
What is the colon? What is the rectum?
The colon and rectum belong to our body's digestive system - together they are also known as the large bowel.
The colon reabsorbs large quantities of water and nutrients from undigested food products as they pass along it.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsOral drug reduces formation of precancerous polyps in the colon, UB researchers find
An oral biologic medication has successfully treated chronic, precancerous inflammation in the intestine, according to results of an animal study authored by an MD/PhD student in the University at Buffalo School of…
15 October 2014
NewsResearchers discover gene that can predict aggressive prostate cancer at diagnosis
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker living next door to the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of…
4 October 2014
NewsYale researchers identify targets for immunotherapy in early-stage breast cancer
Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. The diagnostic test, using RNAScope, measures the…







